Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer

Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute, discusses updated findings from the phase 3 S0221 trial (NCT00070564) investigating alternative adjuvant anthracycline and taxane dosing schedules in patients with high-risk, early breast cancer.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


San Antonio Breast Cancer Symposium

Cleveland Clinic

Cancer Centers

Partner

Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.